52
Participants
Start Date
August 13, 2019
Primary Completion Date
August 29, 2021
Study Completion Date
April 1, 2038
afamitresgene autoleucel (previously ADP-A2M4)
Single infusion of autologous genetically modified afamitresgene autoleucel (previously ADP-A2M4) Dose: 1.0 x109 to 10x109 transduced by a single intravenous infusion
Memorial Sloan-Kettering Cancer Center, New York
National Cancer Institute, Bethesda
Start Madrid-FJD, Fundación Jimѐnez Díaz, Madrid
Hospital Haut Leveque, CHU Bordeaux, Pessac
Mayo Clinic Jacksonville, Jacksonville
Moffitt Cancer Center, Tampa
Vanderbilt, Nashville
Hospital Universitario Virgen del Rocio, Seville
Ohio State University, Columbus
University of Michigan, Ann Arbor
Medical College of WI Froedtert Hospital, Milwaukee
Northwestern University Robert H. Lurie Comprehensive Cancer Center, Chicago
Washington University School of Medicine, St Louis
MD Anderson Cancer Center, Houston
University of Colorado, Aurora
City of Hope, Duarte
Stanford Cancer Center, Palo Alto
Gustave Roussy Cancer Center, Villejuif
Fred Hutch, Seattle
Massachusetts General Hospital, Boston
Dana Farber Cancer Institute, Boston
Princess Margaret Cancer Centre, Toronto
Centre Leon Berard, Lyon
Hospital Universitari Vall D'Hebron, Barcelona
UCLH Cancer Clinical Trials Unit, London
The Christie NHS Foundation Trust, Manchester
Lead Sponsor
Adaptimmune
INDUSTRY